# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001654954-25-006868
**Filing Date:** 2025-6
**Character Count:** 6791
**Document Hash:** 87d12923901f711178e55bc98071cdac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-25-006868.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001654954-25-006868

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250612

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 251042017

**BUSINESS ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

**FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of June 2025

Commission File Number: 001-11960

 **AstraZeneca PLC**

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

 **AstraZeneca PLC**

INDEX TO EXHIBITS

**1. Director/PDMR Shareholding**

12 June 2025

 **Transaction by Person Discharging Managerial Responsibilities**

AstraZeneca PLC (the Company) announces that, on 11 June 2025, it was notified by Aradhana Sarin, Executive Director and Chief Financial Officer, that, on 10 June 2025, Dr Sarin ceased to be beneficially interested in 200 American Depositary Shares (ADSs) of the Company, following the gift of those shares to charity for nil consideration. Each ADS represents one half of an ordinary share of $0.25 each in the Company.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

---

| | | | |
|:---|:---|:---|:---|
| **1**<br>| **Details of the person discharging managerial responsibilities / person closely associated** | **Details of the person discharging managerial responsibilities / person closely associated** | **Details of the person discharging managerial responsibilities / person closely associated** |
| a)<br>| Name | Aradhana Sarin | Aradhana Sarin |
| **2**<br>| **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a)<br>| Position/status<br>| Chief Financial Officer | Chief Financial Officer |
| b)<br>| Initial notification/Amendment | Initial notification | Initial notification |
| **3**<br>| **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| a)<br>| Name | AstraZeneca PLC | AstraZeneca PLC |
| b)<br>| LEI | PY6ZZQWO2IZFZC3IOL08 | PY6ZZQWO2IZFZC3IOL08 |
| **4i**<br>| **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** |
| a)<br>| Description of the financial instrument, type of instrument<br>Identification code | AstraZeneca PLC American Depositary Shares<br>CUSIP: 046353108 | AstraZeneca PLC American Depositary Shares<br>CUSIP: 046353108 |
| b)<br>| Nature of the transaction<br>| Gift of shares to charity for nil consideration | Gift of shares to charity for nil consideration |
| c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| c) | Price(s) and volume(s) | 0<br>| 200 |
| d)<br>| Aggregated information<br>- Aggregated volume<br>- Price<br>| Not applicable - single transaction | Not applicable - single transaction |
| e)<br>| Date of the transaction<br>| 10 June 2025 | 10 June 2025 |
| f)<br>| Place of the transaction<br>| Outside a trading venue | Outside a trading venue |

---

  **<u>AstraZeneca</u>**

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit <u>astrazeneca.com</u> and follow the Company on social media <u>@AstraZeneca</u> 

 **Contacts**

For details on how to contact the Investor Relations Team, please click <u>here</u>. For Media contacts, click <u>here</u>.

 **Matthew Bowden**

 **Company Secretary**

 **AstraZeneca PLC**

 <u>SIGNATURES</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 12 June 2025

---

| |
|:---|
| By: /s/ Adrian Kemp |
| Name: Adrian Kemp |
| Title: Company Secretary |

---

<br>